11 Results for "

hemolysis activity

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "hemolysis activity" in MCE Product Catalog:

7
7 Cited Publications
Cat. No.: HY-110082
CAS No.: 130-89-2
Quinine hydrochloride is an alkaloid extracted from cinchona bark and exhibits oral activity, acting as a potassium channel inhibitor. Quinine hydrochloride modulates the tolerance of red blood cells and presents dose-dependent toxicity and embryonic effects. Quinine hydrochloride is a typical hemolysin that directly lyses red blood cells, with cellular components of red blood cell membranes as its action targets. Quinine hydrochloride disrupts red blood cell membranes and induces hemolysis at high concentrations, while merely weakening the anti-hemolytic capacity of red blood cells at low concentrations. Quinine hydrochloride continuously reduces red blood cell tolerance after in vivo administration, and high doses can also alter blood cell counts. Quinine hydrochloride can be applied to researches related to red blood cell hemolysis, cancer and malaria .
loading...
    loading...
Cat. No.: HY-178476
CAS No.: 3096122-10-7
Research Areas:  

Infection

Anti-MRSA agent 36 (Compound III13) is an antibacterial agent with strong anti MRSA activity (MIC = 1 μg/mL). Anti-MRSA agent 36 targets phosphatidylglycerol (PG) on bacterial membranes, disrupting membrane integrity, leading to DNA leakage and increased ROS. Anti-MRSA agent 36 has advantages such as low cytotoxicity, low hemolysis, difficulty in inducing drug resistance, and good plasma stability. Anti-MRSA agent 36 can be used for the study of skin abscess and systemic infection models .
loading...
    loading...
Cat. No.: HY-178949
Research Areas:  

Infection

MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
loading...
    loading...
Cat. No.: HY-161893
Target:  

Bacterial

Research Areas:  

Infection

Anti-MRSA agent 15 (Compound 9o10) exhibits antibacterial activity, that inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.0625 μg/mL. Anti-MRSA agent 15 exhibits low hemolysis and low cytotoxicity. Anti-MRSA agent 15 exhibits anti-infective in mice .
loading...
    loading...
Cat. No.: HY-179038
CAS No.: 433702-41-1
Target:  

Bacterial

Research Areas:  

Infection

PYO12 is a 3-phenyl-4-phenoxypyrazole type antibacterial compound. PYO12 exhibits selective activity against Gram-positive bacteria with MIC for S. aureus, B. subtilis, S. pneumoniae, and MRSA of 1, 1, 1, and 4 μg/mL respectively. PYO12 has no activity against Gram-negative bacteria. PYO12 can significantly increase bacterial membrane permeability and significantly upregulate cell wall stress-related genes, possibly by binding to the C55-PP part of lipid II. PYO12 shows a concentration-dependent bactericidal effect, has low toxicity to mammalian cells, and does not cause hemolysis. PYO12 can be used to develop new antibiotics targeting bacterial cell wall synthesis .
loading...
    loading...
Cat. No.: HY-P11120
Target:  

Bacterial

Research Areas:  

Infection

NA-CATH is an antibacterial peptide with effective antibacterial activity against Francisella novicida (EC50 = 1.54 µg/mL). NA-CATH does not cause significant hemolysis at a concentration of 100 µg/mL. NA-CATH is commonly used in the study of bacterial infections .
loading...
    loading...
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074

Target:  

Complement System

Research Areas:  

Endocrinology

Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy .
loading...
    loading...
Cat. No.: HY-181677
Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection .
loading...
    loading...
Cat. No.: HY-131975
CAS No.: 901259-15-2
Target:  

Influenza Virus

Research Areas:  

Infection

CBS1194 is a selective group 2 influenza virus inhibitor. CBS1194 binds to the pocket region adjacent to the HA fusion peptide, generates steric hindrance, and blocks the low pH-induced HA conformational rearrangement required for membrane fusion. CBS1194 exerts inhibitory activity in the early stage of viral infection and can inhibit HA-mediated hemolysis. CBS1194 serves as a lead compound for the development of improved influenza virus entry inhibitors. CBS1194 is applicable to studies related to influenza virus infection .
loading...
    loading...
Cat. No.: HY-P992456
Target:  

Complement System

SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
loading...
    loading...
Cat. No.: HY-187723
CAS No.: 353525-62-9
Target:  

P-glycoprotein

Research Areas:  

Cancer

CT-2584 mesylate is an inhibitor targeting CTP:phosphocholine cytidylyltransferase and MDR1, with antitumor activity. CT-2584 mesylate inhibits de novo synthesis of phosphatidylcholine, induces accumulation of phosphatidic acid and phosphatidylinositol in tumor cells, disrupts and dilates the endoplasmic reticulum and mitochondria, induces apoptosis, and inhibits tumor growth. CT-2584 mesylate induces intravascular hemolysis, has mild hypotensive and antiarrhythmic effects, is an intravenous irritant, and may trigger hypersensitivity reactions when combined with Cremophor EL. CT-2584 mesylate can be used in research on neoplastic diseases, hepatocellular carcinoma, solid tumors, malignant pleural mesothelioma, and cancer .
loading...
    loading...
  • 1